• Title/Summary/Keyword: Administration department

Search Result 16,441, Processing Time 0.041 seconds

Antioxidant Activities of Korean Propolis

  • Woo, Soon-Ok;Lee, Kwang-Gill;Kweon, Hae-Yong;Yeo, Joo-Hong;Han, Sang-Mi;Lee, Myeong-Ryeol;Lee, Man-Young
    • Proceedings of the Korean Society of Sericultural Science Conference
    • /
    • 2005.04a
    • /
    • pp.73-73
    • /
    • 2005

  • PDF

Assessment of autoimmunogenic potential of autoimmune disease inducing chmecals using the popliteal lymph node assay

  • Kim, Hyung-Soo;Juno H. Eom;Kim, Jin-Ho;Chung, Seung-Tae;Park, Jae-Hyun;Kang, Sun-Kyung;Kim, Dong-Sub
    • Proceedings of the Korean Society of Toxicology Conference
    • /
    • 2001.05a
    • /
    • pp.113-113
    • /
    • 2001

  • The popliteal lymph node assay (PLNA) was proposed to predict autoimmunogenic potential of xenobiotics. This study was conducted to establish the popliteal lymph node assay(PLNA) and to investigate the measurement of lymphocyte subsets can be utilized as an additional parameter in PLNA.(omitted)

  • PDF

Adenovirus-Mediated Gene Delivery of Tissue Inhibitor of Metalloproteinase-1 Inhibits Migration of B16F10 Melanoma Cell in Wound Migration Assay

  • Seungwan Jee;Hoil Kang;Park, Sehgeun;Park, Misun;Miok Eom;Taikyung Ryeom;Kim, Okhee
    • Proceedings of the Korean Society of Toxicology Conference
    • /
    • 2003.10b
    • /
    • pp.177-177
    • /
    • 2003

  • Tumor cell invasion and metastasis are a complex multistep process that involves the degradation of extracellular matrix proteins by matrix metalloproteinases (MMPs). Tissue inhibitor of metalloproteinase-1 (TIMP-1) acts as a negative regulator of matrix metalloproteinase and thus prevents tumor cell invasion and metastasis by preserving extracellular matrix integrity.(omitted)

  • PDF

Revision of The Korean Pharmceutical Codex, The Third Edition (의약품 등 기준 및 시험방법(제 3개정) 소개)

  • Choi, Myoeng-Sin;Yang, Ji-Sun;Yoo, Tae-Moo;Kim, In-Kyu;Kim, Hye-Soo;Lee, Sun-Hee;Chang, Seung-Yeup;Cho, Jung-Hee;Lee, Su-Jung;Kim, Young-Lim;Kim, Mi-Jeong;Kim, Eun-Jung;Lee, Jong-Pil;Kim, Do-Hoon;Baek, Kyung-Min;Kim, Hee-Sung;Park, Sang-Aeh;Kang, In-Ho;Kim, Eun-Kyung
    • Journal of Pharmaceutical Investigation
    • /
    • v.35 no.3
    • /
    • pp.201-205
    • /
    • 2005

  • The aim of publishing the Korean Pharmaceutical Codex is to update and set specification of essential drugs for humane health. In accordance with speedy development of new drugs and improvement of science and technology, the need of revision of drug specification through the ICH guidelines and discussions between regulatory agency and pharmaceutical industry for the quality assurance of safer and efficient drugs is getting higher. The first edition of Korean Pharmaceutical Codex was published in 1983. Now, the third revision of the Codex is prepared because of the revision of domestic and foreign Pharmacopeias, changes of drug control environment, improvement of science and technology and so on. The aim of 3th edition is to improve the quality of essential drugs through the setting of the required specifications and discussions between the regulatory agency and pharmaceutical industry.

  • https://doi.org/10.4333/KPS.2005.35.3.201 인용 PDF KSCI